Anika Therapeutics, Inc. (NasdaqGS: ANIK)
Health Care · Biotechnology · US
$21.78
+1.30% today · +125.7% 1Y
Anika Therapeutics, Inc. (NasdaqGS: ANIK) operates in the Biotechnology industry within the Health Care sector. The company is valued at $291.48M and employs 235 people.
Over the last twelve months the share price has gained 125.7%, trading between 8.37 and 22.88.
Tweenvest scores Anika Therapeutics, Inc. across four factors: quality 68/100, value 46/100, growth 0/100. Its strongest factor is quality.
ANIK price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $291.48M
- Revenue (TTM)
- $120.65M
- P/E
- —
- EPS
- -0.28
- Dividend yield
- —
- Beta (5Y)
- 0.19
- 52-week high
- $22.88
- 52-week low
- $8.37
- Avg volume (3M)
- —
- Shares outstanding
- 13.38M
- Employees
- 235
- Next earnings
- —
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
- ISIN
- US0352551081
- Founded
- 1983
- Listed since
- May 3, 1993
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $142.62 | -1.69% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.